AC Immune (NASDAQ:ACIU) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts rate AC Immune “Hold” overall: Of five analysts, three recommend buying, one recommends holding and one recommends selling. The average 12-month price target is $7.50, versus a recent share price of $2.58.
• AC Immune reported quarterly EPS of $0.03, beating the consensus estimate of a $0.10 loss, while revenue of $18.67 million exceeded expectations of $9.59 million. However, the company continues to post negative profitability metrics.
• Institutional ownership stands at 51.36%: Goldman Sachs increased its stake by 46.9%, while several other investment firms recently established positions in the clinical-stage biopharmaceutical company.

Shares of AC Immune (NASDAQ:ACIU - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $7.50.

Several analysts have issued reports on ACIU shares. HC Wainwright reissued a "buy" rating on shares of AC Immune in a research note on Wednesday, July 1st. BTIG Research reaffirmed a "buy" rating and issued a $8.00 target price on shares of AC Immune in a report on Wednesday, August 5th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of AC Immune in a research note on Wednesday, August 5th.

AC Immune Stock Up 0.4%

NASDAQ ACIU opened at $2.58 on Thursday. The business has a 50 day moving average price of $2.40 and a two-hundred day moving average price of $2.71. The company has a quick ratio of 1.02, a current ratio of 0.93 and a debt-to-equity ratio of 0.11. The stock has a market cap of $262.57 million, a PE ratio of -4.78 and a beta of 1.59. AC Immune has a fifty-two week low of $2.03 and a fifty-two week high of $4.00.

AC Immune (NASDAQ:ACIU - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13. The firm had revenue of $18.67 million for the quarter, compared to analysts' expectations of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. As a group, sell-side analysts predict that AC Immune will post -0.6 EPS for the current fiscal year.

Hedge Funds Weigh In On AC Immune

Several hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its holdings in AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company's stock worth $58,000 after purchasing an additional 5,920 shares in the last quarter. EFG International AG acquired a new position in AC Immune in the 4th quarter valued at about $41,000. Private Advisor Group LLC acquired a new stake in shares of AC Immune during the third quarter worth $48,000. Susquehanna International Group LLP acquired a new stake in shares of AC Immune in the third quarter valued at approximately $63,000. Finally, Sei Investments Co. acquired a new stake in AC Immune during the second quarter worth about $51,000. Institutional investors own 51.36% of the company's stock.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source